Skip to main content
SpringerLink
Log in

Nonsteroidal Antiinflammatory Drugs

Cyclooxygenase Inhibitors, Disease-Modifying Antirheumatic Agents, and Drugs Used in Gout

  • Chapter
Handbook of Drug Interactions

Part of the book series: Forensic Science and Medicine ((FSM))

Abstract

Nonsteroidal antiinflammatory drugs (NSAIDs) can be divided into two major groups: cyclooxygenase (COX) inhibitors and noncyclooxygenase inhibitors. COX inhibitors represent a wide range of therapeutic agents. Non-COX inhibitors represent the disease-modifying antirheumatic drugs (DMARDs), and the agents used in gout.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Vane JR, Bakhle YS, and Botting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120 (1998).

    Article  PubMed  CAS  Google Scholar 

  2. Deininger MH, Weller M, Streffer J, Mittelbronn M, and Meyermann R. Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol (Berl) 98:240— 244 (1999).

    Article  CAS  Google Scholar 

  3. Meade EA, Smith WL, and DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 268:6610–6614 (1993).

    PubMed  CAS  Google Scholar 

  4. Mitchell JA, Akarasereenont P, Thiememann C, Flower RJ, and Vane JR. Selective of nonsteroidial antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693–11697 (1993).

    Article  PubMed  CAS  Google Scholar 

  5. Vane JR and Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44:1–10 (1995).

    Article  PubMed  CAS  Google Scholar 

  6. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, and Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272–277 (1999).

    Article  PubMed  CAS  Google Scholar 

  7. Bannwarth B, Demotes-Mainard F, Schaeverbeke T, Labat L, and Dehais J. Central analgesic effects of aspirin-like drugs. Fundam Clin Pharmacol 9:1–7 (1995).

    Article  PubMed  CAS  Google Scholar 

  8. Velo GP and Milanino R. Nongastrointestinal adverse reactions to NSAID. J Rheumatol 17(Suppl 20):42–45 (1990).

    Google Scholar 

  9. Gabriel SE, Jaakkimainen L, and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteriodal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115:787–796 (1991).

    Article  CAS  Google Scholar 

  10. Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 19:44–66 (1990).

    Article  PubMed  CAS  Google Scholar 

  11. Weissmann G. Aspirin Sci Am 264:84–90 (1991).

    Article  CAS  Google Scholar 

  12. Vane J. Towards a better aspirin. Nature 367:215–216 (1994).

    Article  PubMed  CAS  Google Scholar 

  13. Lecomte M, Lancoville O, Ji C, DeWitt DL, and Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biochem 269:13207–13215 (1994).

    CAS  Google Scholar 

  14. Diaz-Gonzalez F and Sanchez-Madrid F. Inhibition of leukocyte adhesion: an alternative mechanism for action for anti-inflammatory drug. Immunol Today 19:169–172 (1998).

    Article  PubMed  CAS  Google Scholar 

  15. Willard JE, Lange RA, and Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 327:175–181 (1992).

    Article  PubMed  CAS  Google Scholar 

  16. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 330:1287–1294 (1994).

    Article  PubMed  CAS  Google Scholar 

  17. Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacocinet 17:327–344 (1989).

    Article  CAS  Google Scholar 

  18. Svensson CI and Yaksh TL. The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 42:553–583 (2002).

    Article  PubMed  CAS  Google Scholar 

  19. Douidar SM, Richardson J, and Snodgrass WR. Role of indomethacin in ductus closure: an update evaluation. Dev Pharmacol Ther 11:196–212 (1988).

    PubMed  CAS  Google Scholar 

  20. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 354:2106–2111 (1999).

    Article  PubMed  CAS  Google Scholar 

  21. Norton ME, Merrill J, Cooper BA, Kuller JA, and Clyman RI. Neonatal complications after the administration of endomethacin for preterm labor. N Engl J Med 329:1602–1607 (1993).

    Article  PubMed  CAS  Google Scholar 

  22. Scott, CL and Palmer,RH. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. Aliment Pharmacol Ther 14:443–452 (2000).

    Article  PubMed  CAS  Google Scholar 

  23. Bjarnason I and Thjodleifsson B. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology (Oxford) 38(Suppl 1):24–32 (1999).

    Article  CAS  Google Scholar 

  24. Turck D, Roth W, and Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 35(Suppl 1):13–16 (1996).

    Article  PubMed  Google Scholar 

  25. Rumack BH, Peterson RC, Koch GG, and Amara IA. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 141:380–385 (1981).

    Article  PubMed  CAS  Google Scholar 

  26. Linden CH and Rumack BH. Acetominophen overdose. Emerg Med Clin North Am 2: 103–119 (1984).

    PubMed  CAS  Google Scholar 

  27. Black M. Acetominophen hepatotoxicity. Annu Rev Med 35:577–593 (1984).

    Article  PubMed  CAS  Google Scholar 

  28. Davies NM, McLachlan AJ, Day RO, and Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclooxygenase-2 inhibitor. Clin Pharmacokinet 38:225–242 (2000).

    Article  PubMed  CAS  Google Scholar 

  29. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized, controlled trial. JAMA 282:1921–1928 (1999).

    Article  PubMed  CAS  Google Scholar 

  30. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74:1095–1105 (1999).

    Article  PubMed  CAS  Google Scholar 

  31. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 43:370–377 (2000).

    Article  PubMed  CAS  Google Scholar 

  32. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastrointestinal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117:776–783 (1999).

    Article  PubMed  CAS  Google Scholar 

  33. Morrison BW, Daniels SE, Kotey P, Cantu N, and Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 940:504–508 (1999).

    Article  Google Scholar 

  34. Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, et al. The safety profile, tolerability and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 21:1688–1702 (1999).

    Article  PubMed  CAS  Google Scholar 

  35. Gierse JK, Koboldt C, Hood B, Zhang Y, Zweifel B, Kurumbail R, et al. Valdecoxib: a highly selective and potent inhibitor of COX-2. FASEB 16:A181 (Abst 168.1), 2002.

    Google Scholar 

  36. Green JM and Winickoff RN. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. Arch Intern Med 152:1995–2002 (1992).

    Article  Google Scholar 

  37. Arnold M, Schreiber L, and Brooks P. Immunosuppressive drugs and corticosteroids in the treatment of rheumatoid arthritis. Drugs 36:340–463 (1988).

    Article  PubMed  CAS  Google Scholar 

  38. Fries JF, Williams CA, Ramey D, and Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36:297–306 (1993).

    Article  PubMed  CAS  Google Scholar 

  39. Furst DE. Rational use of disease-modifying antirheumatic drugs. Drugs 39:19–37 (1990).

    Article  PubMed  CAS  Google Scholar 

  40. Wolfe F, Hawley DJ, and Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17:994–1002 (1990).

    PubMed  CAS  Google Scholar 

  41. Stewart CF and Evans WE. Drug-drug interactions with antirheumatic agents: review of selected clinically important interactions. J Rheumatol 17(Suppl 22):16–23 (1990).

    Google Scholar 

  42. Kremer JM and Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Metab 35: 138–145 (1992).

    CAS  Google Scholar 

  43. Arend WP and Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305–315 (1990).

    Article  PubMed  CAS  Google Scholar 

  44. Faulds D, Goa KL, and Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45: 953–1040 (1993).

    Article  PubMed  CAS  Google Scholar 

  45. Epstein WV, Henke CJ, Yelin EH, and Katz PP. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. Ann Intern Med 114:437–444 (1991).

    Article  PubMed  CAS  Google Scholar 

  46. Harriman G, Harper LK, and Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFa treatment. Ann Rheum Dis 58:161–164 (1999).

    Article  Google Scholar 

  47. Jones RE and Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 48:1–4 (1999).

    PubMed  Google Scholar 

  48. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563 (1998).

    Article  PubMed  CAS  Google Scholar 

  49. Garrison L and McDonnell ND.Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 58(Suppl I):1165–1169 (1999).

    Google Scholar 

  50. Jarvis Band Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 57: 945–966 (1999).

    Article  PubMed  CAS  Google Scholar 

  51. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478–486 (1999).

    Article  PubMed  CAS  Google Scholar 

  52. Emmerson BT. The management of gout. N Engl J Med 334:445–451 (1996).

    Article  PubMed  CAS  Google Scholar 

  53. Star VL and Hochberg MC. Prevention and management of gout. Drugs 45:212–222 (1993).

    Article  PubMed  CAS  Google Scholar 

  54. Hande KR, Noone RM, and Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47–56 (1984).

    Article  PubMed  CAS  Google Scholar 

  55. Dan T and Koga H. Uricosurics inhibit urate transporter in rat renal brush border membrane vesicles. Eur J Parmacol 187:303–312 (1990).

    Article  CAS  Google Scholar 

  56. Yu TF, Dayton PG, and Gutman AB. Mutual suppression of the uricosuric effects of sulfinpyrazone and salicylate: a study in interactions between drugs. J Clin Invest 42:1330–1339 (1963).

    Article  Google Scholar 

  57. Yu TF, Dayton PG, and Gutman AB. Mutual suppression of the uricosuric effects of sulfinpyrazone and salicylate: a study in interactions between drugs. J Clin Invest 42:1330–1339 (1963).

    Google Scholar 

Generalreferences

  • Brenner GM. Pharmacology, 1st ed. Philadelphia: Saunders, 2000:317–328.

    Google Scholar 

  • Brody TM, Lamer J, and Minneman KP. Human pharmacology: molecular to clinical, 3rd ed. St. Louis: Mosby, 1998:249–258.

    Google Scholar 

  • Craig CR and Stitzel RE. Modern pharmacology, 4th ed. Boston: Little, Brown, 1990:477–508.

    Google Scholar 

  • Ellenhorn MJ, Schonwald S, Ordog G, and Wasserberger J. Ellenhorn’s medical toxicology: diagnosis and treatment of human poisoning, 2nd ed. Baltimore: Williams & Wilkins, 1997:175–223.

    Google Scholar 

  • Gold Standard Clinical Pharmacology 2000. http://cpip.gsm.com/, May 2002.

    Google Scholar 

  • Hardman JG and Limbird LE. Goodman and Gilman’s: the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill, 2001:687–732.

    Google Scholar 

  • Kalant Hand Roschlau WH. Principles of medical pharmacology, 5th ed. New York: Oxford University Press, 1998:410–427.

    Google Scholar 

  • Katzung BG. Basic & clinical pharmacology, 8th ed. New York: McGraw-Hill, 2001:596–623.

    Google Scholar 

  • Klaassen CD. Casarett and Doul’s toxicology: the basic science of poisons, 5th ed. New York: McGraw-Hill, 1996:969–986.

    Google Scholar 

  • Page C, Curtis M, Sutter M, Walker M, and Hoffman B. Integrated pharmacology, 2nd ed. St. Louis: Mosby International, 2002:437–454.

    Google Scholar 

  • Rang HP, Dale MM, Ritter JM, and Gardner P. Pharmacology, 4th ed. New York: Churchill Livingstone, 2001:229–240.

    Google Scholar 

  • Smith CM and Reynard AM. Essentials of pharmacology, 1st ed. Philadelphia: Saunders, 1995: 147–163.

    Google Scholar 

  • Tryniszewski C. Nurses drug looseleaf. San Francisco: Blanchard & Loeb, 2001:1–796.

    Google Scholar 

Download references

Authors
  1. Imad K. Abukhalaf PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. von Deutsch DDS, PhD, MSCR
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed A. Bayorh PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robin R. Socci PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harris County Medical Examiner Office, Houston, TX, USA

    Ashraf Mozayani PharmD, PhD

  2. University of Miami School of Medicine, Miami, FL, USA

    Lionel P. Raymon PharmD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Abukhalaf, I.K., von Deutsch, D.A., Bayorh, M.A., Socci, R.R. (2004). Nonsteroidal Antiinflammatory Drugs. In: Mozayani, A., Raymon, L.P. (eds) Handbook of Drug Interactions. Forensic Science and Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-654-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-654-6_10

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-424-1

  • Online ISBN: 978-1-59259-654-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation